TY - JOUR
T1 - Safety of the intravenous administration of neurotensin-polyplex nanoparticles in BALB/c mice
AU - Hernandez, Maria E.
AU - Rembao, Jesus D.
AU - Hernandez-Baltazar, Daniel
AU - Castillo-Rodriguez, Rosa A.
AU - Tellez-Lopez, Victor M.
AU - Flores-Martinez, Yazmin M.
AU - Orozco-Barrios, Carlos E.
AU - Rubio, Hector A.
AU - Sánchez-García, Aurora
AU - Ayala-Davila, Jose
AU - Arango-Rodriguez, Martha L.
AU - Pavón, Lenin
AU - Mejia-Castillo, Teresa
AU - Forgez, Patricia
AU - Martinez-Fong, Daniel
N1 - Funding Information:
Sources of Support: This research was supported by ANR-CONACYT Grant # 142947.
PY - 2014/5
Y1 - 2014/5
N2 - Neurotensin (NTS)-polyplex is a gene nanocarrier that has potential nanomedicine-based applications for the treatment of Parkinson's disease and cancers of cells expressing NTS receptor type 1. We assessed the acute inflammatory response to NTS-polyplex carrying a reporter gene in BALB/c mice. The intravenous injection of NTS-polyplex caused the specific expression of the reporter gene in gastrointestinal cells. Six hours after an intravenous injection of propidium iodide labeled-NTS-polyplex, fluorescent spots were located in the cells of the organs with a mononuclear phagocyte system, suggesting NTS-polyplex clearance. In contrast to lipopolysaccharide and carbon tetrachloride, NTS-polyplex did not increase the serum levels of tumor necrosis factor alpha, interleukin (IL)-1β, IL-6, bilirubin, aspartate transaminase, and alanine transaminase. NTS-polyplex increased the levels of serum amyloid A and alkaline phosphatase, but these levels normalized after 24 h. Compared to carrageenan, the local injection of NTS-polyplex did not produce inflammation. Our results support the safety of NTS-polyplex. From the Clinical Editor: This study focuses on the safety of neurotensin (NTS)-polyplex, a gene nanocarrier that has potential in the treatment of Parkinson's disease and cancers of cells expressing NTS receptor type 1. NTS polyplex demonstrates a better safety profile compared with carrageenan, lipopolysaccharide, and carbon tetrachloride in a murine model.
AB - Neurotensin (NTS)-polyplex is a gene nanocarrier that has potential nanomedicine-based applications for the treatment of Parkinson's disease and cancers of cells expressing NTS receptor type 1. We assessed the acute inflammatory response to NTS-polyplex carrying a reporter gene in BALB/c mice. The intravenous injection of NTS-polyplex caused the specific expression of the reporter gene in gastrointestinal cells. Six hours after an intravenous injection of propidium iodide labeled-NTS-polyplex, fluorescent spots were located in the cells of the organs with a mononuclear phagocyte system, suggesting NTS-polyplex clearance. In contrast to lipopolysaccharide and carbon tetrachloride, NTS-polyplex did not increase the serum levels of tumor necrosis factor alpha, interleukin (IL)-1β, IL-6, bilirubin, aspartate transaminase, and alanine transaminase. NTS-polyplex increased the levels of serum amyloid A and alkaline phosphatase, but these levels normalized after 24 h. Compared to carrageenan, the local injection of NTS-polyplex did not produce inflammation. Our results support the safety of NTS-polyplex. From the Clinical Editor: This study focuses on the safety of neurotensin (NTS)-polyplex, a gene nanocarrier that has potential in the treatment of Parkinson's disease and cancers of cells expressing NTS receptor type 1. NTS polyplex demonstrates a better safety profile compared with carrageenan, lipopolysaccharide, and carbon tetrachloride in a murine model.
KW - Biosafety
KW - Cytotoxicity
KW - Nanomaterials
KW - Pro-inflammatory cytokines
UR - http://www.scopus.com/inward/record.url?scp=84900342557&partnerID=8YFLogxK
U2 - 10.1016/j.nano.2013.11.013
DO - 10.1016/j.nano.2013.11.013
M3 - Artículo
C2 - 24333586
AN - SCOPUS:84900342557
SN - 1549-9634
VL - 10
SP - 745
EP - 754
JO - Nanomedicine: Nanotechnology, Biology, and Medicine
JF - Nanomedicine: Nanotechnology, Biology, and Medicine
IS - 4
ER -
